Skip to content

Investor Relations / Publications / Publications Search

Publications Search

Fan W, Philip S, Toth PP, et al. Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: results from National Health and Nutrition Examination Survey (NHANES) 2007-2014. Am J Prevent Cardiol. 2020; epub ahead of print. https://www.sciencedirect.com/science/article/pii/S2666667720300878

Budoff MJ, Muhlestein JB, Bhatt DL, et al. Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: A prospective, placebo-controlled randomized trial (EVAPORATE): Interim Results [published online ahead of print, 2020 Jul 1]. Cardiovasc Res. 2020;cvaa184. doi:10.1093/cvr/cvaa184

https://academic.oup.com/cardiovascres/article-abstract/doi/10.1093/cvr/cvaa184/5865857

Lakshmanan S, Shekar C, Dahal S, Onuegbu A, Kinninger A, Cai A, Birudaraju D, Cherukuri L, Golub I, Rezvanizadeh V, Dailing C, Flores F, Hamal S, Roy SK, Nelson J, Budoff MJ. Association of HDL subclasses with baseline coronary plaque burden by coronary computed tomography angiography (CCTA) from EVAPORATE (effect of Vascepa on improving coronary atherosclerosis in people with high triglycerides taking statin therapy) trial [abstract]. J Am Coll Cardiol 2020;75(11 suppl 1):1624

http://www.onlinejacc.org/content/75/11_Supplement_1/1624

Aberra T, Peterson ED, Pagidipati NJ, Mulder H, Wojdyla DM, Philip S, Granowitz C, Navar AM. The Association between Triglycerides and Incident Cardiovascular Disease: What Is “Optimal”? Journal of Clinical Lipidology 2020;14:438-447.

https://www.lipidjournal.com/article/S1933-2874(20)30079-9/fulltext?dgcid=raven_jbs_etoc_email

Budoff MJ, Bhatt DL, Kinninger A, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020; epub ahead of print.

https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaa652/5898836
Mason R, Sherratt S. Eicosapentaenoic acid (EPA) inhibits human low-density lipoprotein oxidation in a concentration- and time-dependent manner at pharmacologic doses in vitro [abstract EAS19-0568]. Atherosclerosis. 2019;287:E80 https://www.atherosclerosis-journal.com/article/S0021-9150(19)30687-2/fulltext
Eicosapentaenoic acid, but not a mixed omega-3 fatty acid supplement, improved nitric oxide bioavailability in human endothelial cells in vitro.
Mason RP, Dawoud H, Sherratt SCR, Malinski T. Eicosapentaenoic acid, but not a mixed omega-3 fatty acid supplement, improved nitric oxide bioavailability in human endothelial cells in vitro. Presented at the European Atherosclerosis Society meeting, October 4-7, 2020 (virtual).
Eicosapentaenoic acid (EPA) containing phospholipids modulate membrane structure.
Sherratt SCR, Mason RP. Eicosapentaenoic acid (EPA) containing phospholipids modulate membrane structure. Presented at the European Atherosclerosis Society meeting, October 4-7, 2020 (virtual).
copyright
© 2021, Amarin Corporation
Privacy policy  |  Disclaimer
Dublin Office
Spaces South Docklands
Block C
77 Sir John Rogerson's Quay
Dublin 2, D02 VK60
Investor Relations
AMARIN CORPORATION PLC C/O AMARIN PHARMA, INC.
440 ROUTE 22
BRIDGEWATER, NJ 08807
investor.relations@amarincorp.com
Fax:
+1 908 719 3012

Amarin Corporation